Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 2:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: BIS 35 Clear all
Active, not recruiting Phase 3 Interventional Results available

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

NCT02166463
View directory record Official record
Conditions
Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Childhood Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Interventions
Bleomycin Sulfate, Brentuximab Vedotin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Methylprednisolone, Pharmacological Study, Prednisone, Quality-of-Life Assessment, Questionnaire Administration, Vincristine Sulfate
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 22 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
182
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 140 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 17, 2026, 2:25 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

NCT04190550
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Interventions
Cytarabine, Idarubicin Hydrochloride, Navtemadlin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 17, 2026, 2:25 PM EDT
Withdrawn Not applicable Interventional

The BALANCED Anaesthesia Study

NCT02073357
View directory record Official record
Conditions
Effect of General Anesthetic Dose on Recovery From Surgery
Interventions
Light general anaesthesia (BIS = 50), deep general anaesthesia (BIS = 35)
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
60 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Sep 17, 2026, 2:25 PM EDT
Completed Phase 2 Interventional Results available

BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients

NCT02650804
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
BPM31510 Nanosuspension Injection, Gemcitabine
Drug
Lead sponsor
BPGbio
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Gilbert, Arizona • Phoenix, Arizona • Gilroy, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 17, 2026, 2:25 PM EDT
Terminated Not applicable Interventional

Effect of Bispectral Index (BIS) Titrated Propofol Sedation on Lower Esophageal Sphincter Pressures and Esophageal Function in Intensive Care Patients

NCT01173263
View directory record Official record
Conditions
Respiration, Artificial
Interventions
BIS 70 maintained, BIS level 50, BIS 35
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 17, 2026, 2:25 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

NCT04195633
View directory record Official record
Conditions
Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma, Anaplastic Large Cell Lymphoma, Burkitt Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine, Filgrastim, Fludarabine, Mycophenolate Mofetil, Mycophenolate Sodium, Total-Body Irradiation, Treosulfan, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Biospecimen Collection, Computed Tomography, Positron Emission Tomography
Procedure · Drug · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 17, 2026, 2:25 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

NCT01875237
View directory record Official record
Conditions
Leukemia, Myeloma, Myeloproliferative Diseases
Interventions
Fludarabine, Melphalan, Alemtuzumab, Stem Cell infusion, Tacrolimus, Mini Methotrexate, G-CSF, Donor Lymphocyte Infusion (DLI), AP1903, Methylprednisolone, Questionnaire
Drug · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 17, 2026, 2:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Movement Intervention for Memory Enhancement

NCT03475316
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Cognitive Decline, Cognitive Impairment, Dementia, Alzheimer Type
Interventions
Social Dancing, Treadmill Walking
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
65 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Sep 17, 2026, 2:25 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Carfilzomib and Belatacept for Desensitization

NCT05017545
View directory record Official record
Conditions
Highly Sensitized Prospective Kidney Transplant Recipients
Interventions
carfilzomib, belatacept, Bone marrow aspiration
Biological · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 17, 2026, 2:25 PM EDT
Not listed Phase 1Phase 2 Interventional

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

NCT02173093
View directory record Official record
Conditions
Disseminated Neuroblastoma, Recurrent Neuroblastoma
Interventions
IL-2, GD2Bi-aATC, GM-CSF, laboratory evaluations of immune responses
Biological · Other
Lead sponsor
University of Virginia
Other
Eligibility
13 Months to 29 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Detroit, Michigan • New York, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Sep 17, 2026, 2:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cognitive and Emotional Skills to Aid Smoking Prevention

NCT03058991
View directory record Official record
Conditions
Tobacco Smoking
Interventions
Distress Tolerance Intervention, Working Memory Intervention, Control Informational Intervention
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
12 Years to 16 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 17, 2026, 2:25 PM EDT
Completed Not applicable Interventional Results available

Decreasing Alzheimer's Risk Through oNline Choreographed Exercise - Down Syndrome

NCT06537648
View directory record Official record
Conditions
Down Syndrome, Physical Inactivity
Interventions
Decreasing Alzheimer's Risk Through oNline Choreographed Exercise - Down Syndrome Program
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 17, 2026, 2:25 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency

NCT06866119
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Premature Menopause, Metabolic Complications, Endothelial Function (FMD), Estrogen Replacement Therapy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 40 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 17, 2026, 2:25 PM EDT
Recruiting Phase 3 Interventional

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

NCT05675410
View directory record Official record
Conditions
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Interventions
Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin, Computed Tomography, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Fludeoxyglucose F-18, Involved-site Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Prednisolone, Prednisone, Procarbazine Hydrochloride, Questionnaire Administration, Vinblastine Sulfate, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 60 Years
Enrollment
1,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
399
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 295 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 17, 2026, 2:25 PM EDT
Terminated Phase 2 Interventional Results available

Crohn's Allogeneic Transplant Study

NCT01570348
View directory record Official record
Conditions
Crohn Disease
Interventions
Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Mycophenolic Acid, Quality-of-Life Assessment, Tacrolimus, Total-Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 17, 2026, 2:25 PM EDT
Withdrawn Phase 2 Interventional

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

NCT07349771
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography, Cyclophosphamide, Magnetic Resonance Imaging, Mycophenolate Mofetil, Placebo Administration, Positron Emission Tomography, Skin Biopsy, Tacrolimus, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 17, 2026, 2:25 PM EDT
Completed Phase 1 Interventional Results available

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

NCT01607905
View directory record Official record
Conditions
Solid Tumor
Interventions
Selinexor, Acetaminophen
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Tampa, Florida • Detroit, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 17, 2026, 2:25 PM EDT
Completed Phase 1 Interventional

Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia

NCT02446964
View directory record Official record
Conditions
Adult Acute Lymphoblastic Leukemia in Complete Remission, Acute Myeloid Leukemia in Remission, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia in Complete Remission
Interventions
Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total Marrow Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 17, 2026, 2:25 PM EDT
Completed Phase 1 Interventional Results available

Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

NCT01606878
View directory record Official record
Conditions
Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Neuroblastoma
Interventions
Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration, Topotecan Hydrochloride, Vincristine Sulfate
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
13 Months to 21 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 17, 2026, 2:25 PM EDT
Completed Phase 3 Interventional Results available

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

NCT03110562
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Bortezomib, Dexamethasone
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
20
States / cities
Plantation, Florida • Atlanta, Georgia • Honolulu, Hawaii + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 17, 2026, 2:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Trauma-Informed Intervention for Positive Youth Development and Teacher Wellness in Rural Montana

NCT05085392
View directory record Official record
Conditions
Depression, Anxiety, Stress
Interventions
Trauma-Informed Yoga
Behavioral
Lead sponsor
Montana State University
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Livingston, Montana
Source: ClinicalTrials.gov public record
Updated Jul 4, 2023 · Synced Sep 17, 2026, 2:25 PM EDT
Active, not recruiting Phase 1 Interventional

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis

NCT03118492
View directory record Official record
Conditions
Secondary Myelofibrosis
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine, Glycosylated Recombinant Human G-CSF AVI-014, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Tacrolimus, Total-Body Irradiation
Procedure · Drug · Biological + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 17, 2026, 2:25 PM EDT
Recruiting Not applicable Interventional

FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

NCT07446777
View directory record Official record
Conditions
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions
Health Coaching, Prolonged Overnight Fasting (POF), Mediterranean Diet, Supportive Materials
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 17, 2026, 2:25 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

NCT07213960
View directory record Official record
Conditions
FSGS
Interventions
APL2, Placebo
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 17, 2026, 2:25 PM EDT